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Abstract 
Purpose: To validate and culturally adapt Liverpool Adverse Events Profile (LAEP) in Arabic among a 
sample of elderly patients with epilepsy. 
Methods: The face and content validity of the Arabic version of LAEP was ensured by a group of 
healthcare professionals. Undemented elderly patients (≥ 60 years) with seizure disorders, who are on a 
single antiepileptic drug (AED), were recruited from two tertiary care centers in Riyadh, Saudi Arabia. 
Factor analysis was performed to check the construct validity. The reliability was measured using 
Cronbach’s alpha method. 
Results: Seventy-four patients met the inclusion criteria and were interviewed. Most of the participants 
had generalized seizures (67.57 %), and were either illiterate or with elementary school education 
(62.16 %). Their mean age was 68.9 years, and 51.35 % were male. About two-thirds of the participants 
were on either carbamazepine or levetiracetam (66.22 %). Six factors were extracted from the Arabic 
version of LAEP. Cronbach’s alpha of the Arabic version of LAEP was 0.84. The mean overall LAEP 
score was 28.9.  
Conclusion: The Arabic version of LAEP demonstrates good validity and reliability. Similar studies 
should examine its validity and reliability among different epileptic patient populations. 
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Epilepsy is one of the most prevalent 
neurological disorders affecting 70 million people 
worldwide [1]. Lifetime prevalence rate of 
epilepsy in developing countries is reported to be 
almost twice of that in the developed countries 
(10.4 vs 5.8 per 1000 population) [1]. Similar to 
developed countries in Saudi Arabia, the overall 
prevalence of epilepsy in 2001 was reported to 
be 6.54 per 1000 population (95 % confidence 
interval, 5.48 to 7.60) [2]. The same study 
reported the prevalence rate in Saudi adults 
older than 60 years of age to be 5.56 per 1000 
population.  
 
Epilepsy is a complex condition which tends to 
be subject to delays in diagnosis as the 
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symptoms the patients display may not be 
always associated with textbook clinical 
symptoms [3]. This is even more complicated 
when it comes to older adults as this population 
is particularly exposed to atypical clinical 
manifestations [4]. As brain function changes 
with age, epilepsy episodes become less 
frequent and may be complicated with 
uncommon symptoms such as memory loss [5]. 
Age is a known risk factor for epilepsy with 
reported annual incidence rate of 10.8/1000 
patients in patients older than 65 years [6,7]. The 
etiology of new onset epilepsy among older 
adults is usually linked to unknown causes [5]. 
Other causes could be related to cerebrovascular 
disease or neurodegenerative diseases (e.g., 
Alzheimer’s) [5,7].  
 
The management of epilepsy in older adults is 
highly challenging due to a multitude of factors. 
Drug-related factors that change with age include 
efficacy, pharmacokinetics, co-medications and 
medication side effect profiles [4,8]. Indeed, the 
medication regimen in the geriatric population is 
often complicated by three main challenges; 
namely, heightened sensitization to drug action, 
reduction in physiological elimination function 
and poly-pharmacy which may lead to drug-drug 
interactions or reduced drug absorption [9]. All 
these factors contribute to the increased 
prevalence of adverse events among the elderly, 
which is reported to be as high as 30 % [9]. 
 
As opposed to drug serum level monitoring, it is 
now standard to monitor antiepileptic drugs 
(AEDs) using clinical assessment of seizure and 
incidence of adverse events [10]. As adverse 
effect reporting relies greatly on patient reported 
measures, the best way is to use systemic 
standardized patient reported measures for AED 
related symptoms [11]. The Liverpool adverse 
events profile (LAEP) was developed to assess 
adverse effects of AEDs [10]. The scale presents 
several items common with AEDs as a checklist 
of symptoms reported in the last 4 weeks rated 
on Likert scale responses. It is composed of 19 
questions. The LAEP makes it possible for 
clinician to capture subjective symptoms reported 
by the patient in a measurable way [10]. LAEP 
was developed and validated back in 1994 
among English speaking patients with epilepsy in 
the United Kingdom [12]. However, it was later 
translated and validated in different countries and 
languages [13-17]. Although LAEP has been 
translated and validated for use in some non-
English speaking populations [13-17], to our 
knowledge, there are no studies reporting the 
use of LAEP in Arab populations. The aim of this 
study was to translate, validate and use LAEP in 





Instrument and measurement 
 
LAEP is a 19-item self-reported questionnaire, 
designed to measure the frequency of AEDs side 
effects experienced by epileptic patients within 
the past 4 weeks. LAEP covers both CNS and 
non-CNS related adverse effects, scored on 4-
point Likert scale as follows: 1 (always a 
problem), 2 (rarely a problem), 3 (sometimes a 
problem) and 4 (never a problem). The total 
scores range from 19 to 76; scores ≤ 45 
indicates mild to moderate adverse effects, and 
reaches the toxic level if the total score exceeds 
45 [18-20].  
 
LAEP translation and validation 
 
The LAEP was first forward translated by a 
bilingual healthcare professional whose native 
language is Arabic. The Arabic version of LAEP 
was then backward translated by another 
bilingual healthcare professional whose native 
language is English. No significant differences 
were found in the backward translated version 
and the original English version. The Arabic 
version of the LAEP was then reviewed by two 
health outcomes researchers and a neurologist 
for face and content validity. The final Arabic 
version of LAEP was then approved by all the 
research team after addressing all the 
comments. The reliability of LAEP was checked 
using the Cronbach’s Alpha method. The 
international approved guidelines for translation, 
adaptation, and validation of self-reported 
screening instruments were adhered to in this 
study [21]. 
 
Data collection  
 
A medical chart review was performed in the 
departments of neurology at two tertiary care 
centers in the city of Riyadh, Saudi Arabia. 
Patients were considered eligible for inclusion in 
the study if they were diagnosed with seizure 
disorders regardless of the seizure type, aged ≥ 
60 years, cognitively able, and on a single AED. 
Eligible patients were then contacted by three 
healthcare professionals to get their consent for 
a telephone interview after explaining the study’s 
objectives. Once the patients consented, they 
were interviewed. The interview included 
questions about patients’ sociodemographic 
(e.g., age, gender and education), and clinical 
characteristics (e.g., type of seizures & 
antiepileptic drug used) besides LAEP questions.  
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The study was approved by King Saud University 
College of Medicine and King Faisal Specialist 
Hospital and Research Center institutional review 
boards in Riyadh, Saudi Arabia. For ethical 
reasons, the data were code, and no patient 
identifiers were used. The study complied with 
the guidelines of Declaration of Helsinki (DOH) 




Descriptive statistics were conducted using t-test 
and Chi-square test. Factor analysis was also 
conducted to explore the number of factors that 
can be extracted from the Arabic version of 
LAEP. Statistical significance was defined by p < 
0.05. All analyses were performed using a 
statistical software (SAS, version 9.2, SAS 




Out of 131 patients, who met the inclusion 
criteria and were contacted, 74 patients (56.5 %) 
consented to participate in the study and were 
interviewed. The mean age of participants was 
68.9 years. Approximately, 50 % of the 
participants were male and illiterate. Almost 26 % 
of the participants experienced at least one 
seizure episode within the past 6 months, 
however, the majority were seizure free.   About 
two-thirds of the participants had generalized 
seizures and the remaining had partial seizures. 
Most of the participants were on either 
carbamazepine (36.49 %) or levetiracetam 
(29.73 %). Participants’ characteristics are 
shown in Table 1.  
 
The frequencies of the adverse AED effects 
based on LAEP are shown in Figure 1. Adverse 
effects that were reported as always or 
sometimes on the LAEP were as follows: 
Disturbed sleep (29.73 %), upset stomach (25.67 
%), aggressiveness (22.98 %), sleepiness (22.79 
%), Memory problems (20.27 %), headache 
(20.27 %), nervousness (18.2 %), weight gain 
(18.2 %), hair loss (17.57 %), depression (17.57 
%), restlessness (16.22 %), difficulty in 
concentration (16.22 %), unsteadiness (12.17 
%), blurred vision (10.82 %), trouble with mouth 
or gum (10.81 %), shaky hands (9.46 %), 
tiredness (8.1 %), skin problems (6.75 %), and 
dizziness (5.4 %). The mean scores of LAEP 
items are presented in Table 2. The overall mean 
score of LAEP was 28.9, ranging between 19 
and 56.  
 
Table 1: Sociodemographic and clinical characteristics 




Age (yr) 68.9 ± 7.4 
Gender  
Male 38 (51.35) 
Female 36 (48.65) 
Education  
Illiterate 37 (50) 
Elementary school 9 (12.16) 
Intermediate school 4 (5.41) 
High school diploma 8 (10.81) 
Associate degree 7 (9.46) 
Bachelor degree or more 9 (12.16) 
Experienced seizures in the 
past 6 months   
19 (25.68) 
Type of seizure  
Generalized 50 (67.57) 
Partial 24 (32.43) 
Antiepileptic drug (AED)  
Phenytoin 12 (16.22) 
Carbamazepine 27 (36.49) 
Valproic acid 11 (14.86) 
Lamotrigine 1 (1.35) 
Levetiracetam 22 (29.73) 
Topiramate 1 (1.35) 
Data are expressed as mean ± standard deviation for 
age and in frequency and percentage for other 
variables 
 
Table 2: Mean score of LAEP items 
 
Adverse effect Mean ± SD 
Unsteadiness  1.5  0.8 
Tiredness  1.3  0.7 
Restlessness  1.5  1.0 
Feelings of anger or aggression 
to others 
1.7  1.0 
Nervousness and/or agitation 1.6  0.9 
Headache  1.6  0.9 
Hair loss 1.5  0.9 
Problems with skin 1.3  0.7 
Double or blurred vision 1.4  0.8 
Upset stomach  1.7  1.1 
Difficulty in concentrating 1.5  1.0 
Trouble with mouth or gums   1.3  0.8 
Shaky hands 1.4  0.8 
Weight gain 1.6  1.0 
Dizziness  1.2  0.6 
Sleepiness  1.8  1.2 
Depression  1.5  1.0 
Memory problems 1.6  1.0 
Overall score 28.9 ± 8.9 
 
Using factor analysis, six factors were extracted 
using the eigenvalue cutoff point of ≥1 (Figure 2). 
The factors were labelled as follows: (1) Psycho-
motor symptoms (dizziness, unsteadiness, 
headache, hair loss, and upset stomach); (2) 
Neuro-somatic symptoms(double or blurred 
vision, memory problems, problems with skin,  
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   Figure 1: Frequency of AED adverse effects based on LAEP scale 
 
 
Figure 2: Scree plot of the number of factors that can be extracted from the Arabic version of LAEP and their 
Eigen values 
 
and trouble with mouth or gums); (3) Behavioral 
symptoms (feelings of anger or aggression to 
others, and nervousness and/or agitation); (4) 
Mental disturbance symptoms (tiredness, 
disturbed sleep, depression, and restlessness)  
(5) Hypersomnia symptoms (weight gain and 
sleepiness); and (6) dementia-like symptoms  
(shaky hands and difficulty in concentrating). The 
Kaiser-Meyer-Olkin measure of sampling 
adequacy suggested that the study sample was 
factorable (KMO = 0.67). The internal 
consistency of the Arabic version of the LAEP 
was good (Cronbach’s alpha = 0.84). Table 3 
shows the names of the extracted factors with 




For many decades, therapeutic drug monitoring 
(TDM) has been and still the cornerstone in 
optimizing the dosage regimen of AEDs in order 
to control seizures and minimize their side effects 
[22]. However, with the advent of the patient-
centered care era, which has been taking root 
recently, healthcare researchers and providers 
alike are beginning to believe more in patient 
reported outcomes (PROs) [23].  Questionnaires 
and scales that measure patients’ experiences 
with different treatment strategies including 
medications are gaining ground in clinical 
practice over the last two decades [24]. 
Questionnaires such as the LAEP that quantify 
patients’ perceptions and experiences with 
medications in primary care are widely used 
nowadays [10-12]. In this study we aimed to 
translate and validate for the first time the LAEP 
in Arabic, which is a widely used questionnaire to 
quantify patients’ experienced side effects with 
AEDs. However, we decided to focus on the 
geriatric patient population ( ≥ 60 years) due to 
the fact that this segment of patients is largely 
ignored and faces tremendous problems with  
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Table 2: Extracted factors from Arabic version of LAEP 
 














Dizziness  0.76      0.67 
Unsteadiness  0.73      0.67 
Headache  0.69      0.62 
Hair loss 0.68      0.58 
 Upset stomach  0.67       0.66 
Double or blurred 
vision 
 0.79     0.74 
Memory problems  0.71     0.58 
Problems with skin  0.66     0.67 
Trouble with mouth or 
gums   
 0.65     0.73 
nervousness and/or 
agitation 
  0.95    0.93 
Feelings of anger or 
aggression to others 
  0.94    0.94 
Tiredness     0.69   0.62 
Disturbed sleep     0.67   0.48 
Depression     0.59   0.59 
Restlessness     0.47   0.51 
Weight gain     0.76  0.65 
Sleepiness      0.75  0.64 
Shaky hands      0.87 0.81 
Difficulty in 
concentrating 
     0.46 0.73 
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medication adherence especially AEDs as well 
as in communication with healthcare providers 
[25]. Further, elderly patients may become more 
susceptible to the adverse effects of medications 
due to their diminished physical reserve [7-8].  
 
Similar to previous studies, the Arabic version of 
the LAEP demonstrated good reliability 
(Cronbach’s alpha = 0.84) [13-17]. In addition, 
the face and content validity was checked by 
multiple healthcare professionals and deemed to 
be good. However, six factors were retained from 
the factor analysis that was performed to check 
the construct validity of the Arabic version of 
LAEP contrary to Baker et al and other validation 
studies that retained 3 factors only [13-17]. This 
could be explained by language differences and 
the fact that only elderly patients were included in 
the study. 
 
In this study, the lowest and highest LAEP 
scores were 19 and 56, respectively.  However, 
the mean LAEP score was 28.9, which is 
significantly lower than the ones reported in other 
studies, and suggests that the majority of 
patients in the study experienced low grade 
adverse AEDs effects [13-17].  This can be due 
to the fact that only patients on a single AED 
were included in the study as well as the 
tolerance to the AEDs adverse effects that 
patients might have developed over the years of 
treatment. Disturbed sleep, upset stomach, 
aggressiveness, sleepiness, memory problems 
and headache were the most commonly reported 
symptoms among more than 20 % of the 
participants. 
 
Limitations of the study  
 
Although this study is the first to validate the 
LAEP in Arabic, it has several limitations. First, 
only patients on a single AED were included in 
the study. Second, the study was limited to 
elderly patients (≥ 60 years) only. Third, the 
sample size of the study is small. Therefore, the 




An Arabic version of LAEP has been has been 
established. It demonstrates good validity and 
reliability and makes it easier to screen Arabic 
speaking epileptic patients for common side 
effects of AEDs. Future studies should examine 
the validity and reliability of the Arabic version of 
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